Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity - PubMed (original) (raw)
Review
Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity
Nathalie Vigneron et al. Curr Opin Immunol. 2012 Feb.
Abstract
Protein degradation by the proteasome releases peptides that can be loaded on MHC class I molecules and presented to cytolytic T lymphocytes. Several mechanisms were recently found to increase the diversity of antigenic peptides displayed at the cell surface, thereby maximizing the efficacy of immune responses. The proteasome was shown to produce spliced antigenic peptides, which are made of two fragments initially not contiguous in the parental protein. Different proteasome subtypes also produce distinct sets of antigenic peptides: the standard proteasome and the immunoproteasome, containing different catalytic subunits, have different cleavage specificities and produce different sets of peptides. Moreover, recent work confirmed the existence of two additional proteasome subtypes that are intermediate between the standard and the immunoproteasome, and each produce a unique peptide repertoire.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- Analysis of the processing of seven human tumor antigens by intermediate proteasomes.
Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ. Guillaume B, et al. J Immunol. 2012 Oct 1;189(7):3538-47. doi: 10.4049/jimmunol.1103213. Epub 2012 Aug 27. J Immunol. 2012. PMID: 22925930 - Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ. Guillaume B, et al. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. doi: 10.1073/pnas.1009778107. Epub 2010 Oct 11. Proc Natl Acad Sci U S A. 2010. PMID: 20937868 Free PMC article. - Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5.
Dalet A, Vigneron N, Stroobant V, Hanada K, Van den Eynde BJ. Dalet A, et al. J Immunol. 2010 Mar 15;184(6):3016-24. doi: 10.4049/jimmunol.0901277. Epub 2010 Feb 12. J Immunol. 2010. PMID: 20154207 - Standard and immunoproteasomes show similar peptide degradation specificities.
Zanker D, Chen W. Zanker D, et al. Eur J Immunol. 2014 Dec;44(12):3500-3. doi: 10.1002/eji.201445272. Eur J Immunol. 2014. PMID: 25399798 Review. - Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.
Vigneron N, Van den Eynde BJ. Vigneron N, et al. Biomolecules. 2014 Nov 18;4(4):994-1025. doi: 10.3390/biom4040994. Biomolecules. 2014. PMID: 25412285 Free PMC article. Review.
Cited by
- Caged aminoluciferin probe for bioluminescent immunoproteasome activity analysis.
Loy CA, Trader DJ. Loy CA, et al. RSC Chem Biol. 2024 Jul 16;5(9):877-883. doi: 10.1039/d4cb00148f. eCollection 2024 Aug 28. RSC Chem Biol. 2024. PMID: 39211472 Free PMC article. - Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.
Yang K, Halima A, Chan TA. Yang K, et al. Nat Rev Clin Oncol. 2023 Sep;20(9):604-623. doi: 10.1038/s41571-023-00789-4. Epub 2023 Jun 16. Nat Rev Clin Oncol. 2023. PMID: 37328642 Review. - The new oncogene transmembrane protein 60 is a potential therapeutic target in glioma.
Yang F, Zhang X, Wang X, Xue Y, Liu X. Yang F, et al. Front Genet. 2023 Jan 20;13:1029270. doi: 10.3389/fgene.2022.1029270. eCollection 2022. Front Genet. 2023. PMID: 36744183 Free PMC article. - Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model.
Bausart M, Vanvarenberg K, Ucakar B, Lopes A, Vandermeulen G, Malfanti A, Préat V. Bausart M, et al. Pharmaceutics. 2022 May 10;14(5):1025. doi: 10.3390/pharmaceutics14051025. Pharmaceutics. 2022. PMID: 35631612 Free PMC article. - Neo-Splicetopes in Tumor Therapy: A Lost Case?
Kloetzel PM. Kloetzel PM. Front Immunol. 2022 Feb 21;13:849863. doi: 10.3389/fimmu.2022.849863. eCollection 2022. Front Immunol. 2022. PMID: 35265089 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials